Fingerprint Diagnostics
Fingerprint Dx develops advanced blood-based DNA methylation tests for early cancer detection. Their proprietary molecular assay analyzes DNA methylation markers in cell-free DNA to create cancer methylome maps, using machine learning to detect and classify cancer and identify its organ of origin. Their TissueFingerprint classifier detects 15 cancer types with 98% sensitivity and 96% accuracy in cancer type prediction, while the BloodFingerprint classifier detects lung, colon, stomach, liver, and prostate cancers with 89% sensitivity and 90% accuracy in organ prediction. They are conducting a large clinical trial program in Central and Southern Europe to validate their technology, partnering with healthcare and academic institutions. Their approach aims to detect cancer early when it is most treatable, improving patient outcomes.
Fingerprint Diagnostics
Fingerprint Dx develops advanced blood-based DNA methylation tests for early cancer detection. Their proprietary molecular assay analyzes DNA methylation markers in cell-free DNA to create cancer methylome maps, using machine learning to detect and classify cancer and identify its organ of origin. Their TissueFingerprint classifier detects 15 cancer types with 98% sensitivity and 96% accuracy in cancer type prediction, while the BloodFingerprint classifier detects lung, colon, stomach, liver, and prostate cancers with 89% sensitivity and 90% accuracy in organ prediction. They are conducting a large clinical trial program in Central and Southern Europe to validate their technology, partnering with healthcare and academic institutions. Their approach aims to detect cancer early when it is most treatable, improving patient outcomes.